The Russian Scientific Center for Molecular Diagnostics and Treatment and Searle Pharma started to construct a pharma manufacturing facility in Moscow, Izvarino in 1997. Credit: Gorodenkoff/
The facility became operational in September 1998. Credit: Blackator/
Izvarino Pharma offers a range of medicines for obesity, type 2 diabetes, CNS and oncological diseases. Credit: Sonis Photography/

Izvarino Pharma, a Russia-based pharmaceutical company, opened a $30m medication production plant in Izvarino, Moscow, in 1998. The production operation at the facility began in 1999.

The plant reduced production costs by 50%. It produces 300 million tablets and capsules per year of more than 15 titles.

The construction of the facility began in 1997 by the Russian Scientific Center for Molecular Diagnostics and Treatment and Searle Pharma, a pharmaceutical company based in the US, in the Moscow area, close to the region of Izvarino.

The $30m medication production facility, which was built in complete accordance with international good manufacturing practice (GMP) standards, guarantees product quality and safety.

The plant was subsequently acquired by global pharmaceutical company Pfizer in 2003. Furthermore, a new set of investors acquired ownership of the business in 2007 and changed its name to Izvarino Pharma.

In 2021, Izvarino Pharma joined the Server Life Science group of companies. In 2014, Izvarino Pharma was certified and granted a license to produce new medicines, which they renewed in 2018.

Izvarino Pharma facility details

The site covers an area of 3ha (30,000m²) and includes two buildings. The first building includes a manufacturing, laboratory, and office space, while the second has a finished products warehouse.

The 6,200m² facility enables the whole solid form production cycle, including blending and granulation, coating, tabletting and capsulation, primary and secondary packaging, analysis and quality control, storage, distribution and logistics, as well as research and development and analytical work.

By implementing upgrades, the company has expanded its production capacity, resulting in an annual output of 12 million packs.

Izvarino Pharma adheres to modern quality management principles, including GMP standards, at all stages of drug production.

Equipment for the plant was supplied by companies based in Germany, England, Italy, France and the US. The major contractor was Domus, along with Jacobs Engineering. Laboratory equipment was supplied and installed by Intertech, which also provided personnel training.

Izvarino product details

Izvarino is actively promoting the replacement of expensive imported products with more affordable alternatives, offering more than 40 licensed and approved products with proven efficacy and long-term experience. Branded generics are products with improved consumer properties, categorised as generic+ products.

The product range includes anti-gout drugs, cardiovascular system, central nervous system, endocrinology, gynaecology, gender psychology, gastrointestinal tract, infections, inflammation, oncology, and transplantation.

Izvarino Pharma focuses on treating obesity and type 2 diabetes through its products such as Goldline, Listat, metformin, and metformin MB. Their medicines for central nervous system diseases are vinpocetin, pregabalin, valproic acid, and memantine, and for oncological diseases are imatinib, terabinth, and capecitabine.

Izvarino Pharma reconstruction details

Izvarino Pharma plant is reequipped with new facilities. The company promotes its preparations and partners with foreign companies for women’s health treatment. Exelgyn Laboratories, a French company that produces Mifegyne, is the first partner.

Financing details

The facility was donated by the National Research Center for Molecular Diagnostics and Treatment (VNTSMDL), owned by the all-Russian Scientific Centre of Molecular Diagnosis and Treatment RAO (Biopreparat).

American companies invested $24m in the project. Searle Pharma invested the largest sum while the US Agency for International Development (US-AID) contributed $6m.